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Alterednaturalkiller(NK)cellfunctionisacomponent oftheglobalimmunedysregulationthatoccursinadvanced malignancies.
Another condition associated with altered NK homeostasis is normal pregnancy, where robust inﬁltration with CD16− CD9+ NK
cellscanbeidentiﬁedindecidualtissues,alongwithaconcomitantexpansionofCD16−NKcellsinthematernalperipheralblood.
In metastatic melanoma, we identiﬁed a similar expansion of peripheral blood CD16− NK cells (median 7.4% in 41 patients with
melanoma compared with 3.0% in 29 controls, P<. 001). A subset of NK cells in melanoma patients also expresses CD9, which
is characteristically expressed only on NK cells within the female reproductive tract. Expansion of CD16− NK cells was associated
with elevated plasma transforming growth factor-beta (TGF-β levels (median 20ng/ml, Spearman’s ρ = 0.81,P = .015)). These
ﬁndings suggest the possibility of exploring anti-TGF-β therapy to restore NK function in melanoma.
1.Introduction
Natural killer (NK) cells are a critical component of innate
immunity and tumor immunosurveillance in melanoma and
othermalignancies[1].ImpairmentofNKcytolyticfunction
has previously been described in melanoma [2, 3]. Another
physiologic condition associated with a shift in NK home-
ostasis toward a noncytolytic phenotype is normal human
pregnancy, where expansion of weakly cytotoxic CD56bright
CD16dim/− NK cells (hereafter referred to as CD16− NK
cells to distinguish from CD56bright NK cells, which may
represent predecessors to CD16+ mature NK cells [4]) can
be seen both in the peripheral blood [5]o fp r e g n a n tw o m e n
and enriched at the fetomaternal interface [6]. Specialized
decidual NK cells at the fetomaternal interface serve an
immunoregulatory/angiogenic function to support placen-
tation and are phenotypically identiﬁed by the expression
of CD9, a tetraspanin involved in cell adhesion [7]. Mature
peripheral blood CD16+ NK cells can be transformed into
CD16− CD9+ NK cells with a decidual phenotype after pro-
longed exposure to transforming growth factor-beta (TGF-β
[8], a cytokine with pleiotropic immunologic eﬀects includ-
ing potential regulation of NK function at the host/tumor
interface [9].) Here, we test the hypothesis that CD16− NK
cells are expanded in the peripheral blood of melanoma
patients as previously described in normal pregnancy. Addi-
tionally, we assessed CD9 expression on peripheral blood
NK cells and determined the presence of an association with
elevated TGF-β levels in patients with metastatic melanoma.
2.MaterialsandMethods
2.1. Collection of Patient Biospecimens. NK subset analysis
was performed on the peripheral blood of 41 patients with2 Clinical and Developmental Immunology
untreated metastatic melanoma, 39 of whom had plasma
available for multiplex cytokine arrays. For comparison, NK
subsets were also analyzed in 29 healthy control individuals.
Samples from patients with metastatic melanoma (newly
diagnosed, previously untreated) as well as healthy volun-
teers/controls were collected under separate specimen bank-
ingprotocols.Bothprotocolswerereviewedandapprovedby
the Mayo Clinic Institutional Review Board for use in these
studies. Written informed consent was obtained from partic-
ipants for banking of blood and tissue samples, and Mayo
Clinic IRB approvals were granted for the speciﬁc studies
detailed in this work. Peripheral venous blood (50–90mL)
was drawn into heparinized Vacutainer tubes that were
processed and separated into plasma and peripheral blood
mononuclear cells (PBMCs) following gradient centrifuga-
tion using Ficoll-Paque (GE Healthcare, Uppsala, Sweden).
Plasma was collected and immediately frozen at -80◦Ci n
1mL aliquots. The PBMCs were collected, washed in phos-
phate buﬀered saline, counted, diluted to 1 × 107/mL, and
viablyfrozenin90%cosmiccalfserum(HycloneInc.,Logan,
UT) and 10% dimethylsulfoxide (Sigma, St. Louis, MO).
2.2. Evaluation of NK Cell Subsets by Flow Cytometry.
Previously frozen PBMCs (0.5–1.0 × 106 cells/mL) from
patients with metastatic melanoma as well as healthy control
patients were used for determination of NK cell subsets.
Four-color ﬂow cytometry was performed using an LSRII
ﬂow cytometer (Becton Dickinson), and CellQuest software
(Becton Dickinson, San Jose, CA) was used for data analysis.
The following anti-human monoclonal antibodies were used
in PBMC immunophenotyping for ﬂow cytometry: anti-
CD3-PE-Cy5, anti-CD56-phycoerythrin, anti-CD16-Alexa
Fluor 647, and anti-CD9 ﬂuorescein isothiocyanate (BD
Pharmingen).
2.3. Plasma Cytokine, Chemokine, and Growth Factor Con-
centrations. Protein levels for cytokines, chemokines, and
growth factors, including IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-
6, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-15, IL-17, G-CSF,
GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α,M I P - 1 β,T N F - α,
and VEGF, were measured using either the Bio-Plex cytokine
assay (Bio-Rad, Hercules, CA, 28 patients) or Invitrogen
BioSourcemultiplexcytokineassay(InvitrogenCorporation,
Carlsbad, CA, 11 patients) as per manufacturer’s instruc-
tions. Brieﬂy, patient plasma was diluted 1:4 in dilution
buﬀer and 50μL was added to washed, ﬂuorescently dyed
microspheres (beads) to which biomolecules of interest are
bound.Thebeadsanddilutedpatientplasmawereincubated
for 30 minutes at room temperature with agitation. After
the incubation, the beads were washed in wash buﬀer and
placed in 25μL of detection antibody and incubated for 30
minutes as described above. After washing, the beads were
placedinstreptavidin-phycoerythrin,incubated,andwashed
a ﬁnal time. The bound beads were resuspended in 125
microliters of assay buﬀer and read with the Luminex plate
reader (Bio-Rad, Hercules, CA). Protein concentrations were
determined using a standard curve generated using the high
PMT concentrations with sensitivity from 10–1000pg/mL.
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Figure 1: Patients with metastatic melanoma have expanded
peripheral blood CD16− NK cell pools. Box-plot with quartiles
depicting percentage of CD16− NK cells in peripheral blood from
41 metastatic melanoma patients (median 7.6%) compared with 29
healthy controls (median 3.1%, Mann–Whitney P<. 001).
2.4. Determination of Plasma TGF-β Levels by ELISA. Plasma
levels of TGF-β1 were determined by ELISA using a duoset
antibody pair (R&D Systems, Minneapolis, MN) as per
manufacturer’s instructions.
2.5. Statistical Analysis. Diﬀerences in percentage of periph-
eral blood CD16− NK cells between healthy subjects and
patients with metastatic melanoma were determined by the
Mann–Whitney U test. Correlations between TGF-β levels
and the percentage of NK cell subsets ware determined
by Spearman’s ρ. Correlations between cytokines were
estimated by the pairwise method.
3. Results and Discussion
Circulating CD16− NK cells were expanded 2.5-fold in
patients with melanoma compared with healthy controls
(Figure 1, median 7.4% compared with 3.0%, P<. 001). The
Median CD16+ NK cell count was 0.56×109 per liter (range
0.03–1.53 × 109 per liter), and the median CD16− NK cell
count was 0.11 × 109 per liter (range 0.01–0.50 × 109 per
liter) in patients with metastatic melanoma, within range of
published values for NK cells in healthy adults [10]. None
of the tested multiplex plasma cytokines or growth factors
correlated strongly with the distribution of NK cells subsets
(Figure 2). Median and range of these parameters are listed
in Table 1.
Normal peripheral blood CD16+ NK cells incubated
in culture with TGF-β result in a transition to a CD16−
CD9+ phenotype resembling decidual NK cells [8]. Since,
like pregnancy [11], metastatic melanoma is a condition
associated with elevated TGF-β levels [12], we next sought
to evaluate whether NK cells in the peripheral blood of
patients with metastatic melanoma might also express CD9
or exhibit any subset correlation with plasma levels of TGF-
β.Eightuntreatedmelanomapatientshad14uniquesamplesClinical and Developmental Immunology 3
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Figure 2: Color map on pairwise correlations between NK subsets and plasma cytokines and growth factors. None of the tested multiplex
cytokines or growth factors were strongly associated with the percentages of CD16+ or CD16− NK cells.
of PBMCs available for further phenotypic NK testing with
CD9 and corresponding plasma for TGF-β determination.
Representative plots from the experiments demonstrat-
ing CD16− CD9+ NK cells in the peripheral blood of
metastatic melanoma patients are shown in Figure 3.C D 9
was expressed on a median of 24% of peripheral blood NK
cells in patients with metastatic melanoma (Figure 3,r a n g e
13.4–37.9%). This alteration in NK homeostasis toward a
CD16−phenotypewasstronglycorrelatedwithplasmalevels
of TGF-β in these patients (Figure 4(a), median 20ng/ml,
Spearman’s ρ = 0.81, P = .015). A moderate correlation
between CD16− CD9+ NK cells and TGF-β was observed
that did not meet statistical signiﬁcance (Figure 4(b),S p e a r -
man’s ρ = 0.48, P = .23).
Bias of NK subsets toward a less cytotoxic and more
immunoregulatory phenotype may be a reﬂection of an
overall immunosuppressive milieu in patients with advanced
malignancies. The association of expanded CD16− NK cells
withelevatedTGF-βlevelshasalsobeenidentiﬁedinpatients
with esophageal squamous cell carcinoma [13] and gastric
cancer [14]. Other examples of altered NK homeostasis
in cancer exist, including relative expansion of weakly
cytolytic CD16− NK cells in patients with hepatocellular
carcinoma compared with healthy controls [15], in the
peripheral blood and peritoneal ﬂuid of ovarian cancer
patients [16], and in the stroma of nonsmall-cell lung cancer
primary tumors [17]. Our results suggest that CD16− CD9+
NK cells may not be speciﬁc for the female reproductive
tract as once thought, but may instead be reﬂective of
systemic immunomodulation that occurs in melanoma and
potentially other conditions associated with high levels of
TGF-β.Ourﬁndingswillrequirevalidationbutpreliminarily
support further investigation into anti-TGF-β therapy as a
part of cancer immunotherapy.
Recent reports have begun to elucidate the mechanisms
by which TGF-β suppresses NK function. The NK cell acti-
vatingreceptorNKG2Dhasrecentlybeendescribedasdown-
regulated by TGF-β in cancer patients [18]. Additionally, in
the presence of TGF-β NK, cells stimulated through CD16
show reduced T-BET expression and diminished production
of interferon-gamma and tumor necrosis factor-alpha, fur-
ther demonstrating the suppressive eﬀects of TGF-β on NK
cells. In melanoma, we have shown that chemotherapeutic
intervention with bevacizumab, carboplatin, and paclitaxel
can at least transiently alter an individuals’ immunologic
response to the tumor [19]. However, most patients with4 Clinical and Developmental Immunology
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Figure 3: CD9 expression on NK cells in patients with melanoma. Scatterplot demonstrating CD9 expression in a subset of peripheral
blood CD16− NK cells from patients with metastatic melanoma (right). CD9, a marker speciﬁc for decidual NK cells is, absent on NK
cells from healthy individuals (left). Gating is set on CD3− CD56+ lymphocytes. Numbers represent percentages of total NK cells in each
quadrant.
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Figure 4: Correlation of TGF-β with (a) the CD16− NK cell subset and (b) the CD16− CD9+ subset. Expansion of the CD16− phenotype
NK cell subset was strongly correlated with plasma levels of TGF-β in these patients. A moderate correlation between CD16− CD9+ NK cells
and TGF-β did not meet statistical signiﬁcance.
metastatic melanoma eventually succumb to complications
of the cancer that involve systemic dysregulation of immu-
nity, which appears to be manifest in part by altered NK cell
homeostasis. In future studies, we will determine whether
the observed alteration in NK homeostasis is prognostic or
predictive of treatment response and survival in metastatic
melanoma.
4. Conclusion
Our results suggest that identiﬁcation and modulation of
an immunosuppressive cytokine milieu, for example, high
plasma levels of TGF-β might allow for restoration of
endogenous antitumor immunity, including recovery of NK
cytolytic function, and ultimately improve outcomes of
melanoma therapy.
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Table 1: Absolute NK cells counts and plasma cytokine/growth
factor levels in patients with metastatic melanoma. Cell counts
are measured in cells ×109 per liter, and plasma cytokines/growth
factors are measured in picograms/milliliter.
Median Minimum Maximum
Absolute NK cell count 0.64 0.13 1.66
Absolute CD16+ NK 0.56 0.03 1.53
Absolute CD16− NK 0.11 0.01 0.50
IL-1b 3.22 0.00 1216.46
IL-1ra 80.90 0.19 4130.51
IL-2 7.42 0.00 463.38
IL-4 3.95 0.00 129.84
IL-5 1.02 0.00 17.22
IL-6 11.83 0.41 2307.25
IL-7 5.38 0.58 250.24
IL-8 11.45 0.06 2439.86
IL-10 4.22 0.00 175.74
IL-12p70 6.88 0.00 1637.86
IL-13 6.07 0.00 162.68
IL-15 9.22 0.00 709.06
IL-17 6.36 0.00 96.60
TNF-α 13.28 0.00 439.51
G-CSF 16.22 0.42 622.01
GM-CSF 70.58 0.00 419.91
IFN-γ 8.85 0.00 325.81
IP-10 77.56 0.73 3679.56
MCP-1 46.28 0.02 19679.10
MIP-1a 8.11 0.00 907.85
MIP-1b 79.34 0.27 13000.21
VEGF 15.32 0.00 161.15
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